BridgeBio Pharma’s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement